Mer­ck claims a need­ed win for Keytru­da with in­ter­im OS da­ta in head and neck can­cer

Mer­ck has stocked up on da­ta to sup­port mov­ing Keytru­da up as a first-line ther­a­py for head and neck squa­mous cell car­ci­no­ma.

An in­ter­im analy­sis of the Keynote-048 study sug­gest­ed that the check­point in­hibitor sig­nif­i­cant­ly im­proved over­all sur­vival — one of two pri­ma­ry end­points — in pa­tients whose tu­mors ex­pressed PD-L1. The dual-pri­ma­ry end­point of pro­gres­sion-free sur­vival, how­ev­er, has not been reached.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN